ATE303383T1 - Bizyklische inhibitoren von glycogen synthase kinase 3 - Google Patents

Bizyklische inhibitoren von glycogen synthase kinase 3

Info

Publication number
ATE303383T1
ATE303383T1 AT00989272T AT00989272T ATE303383T1 AT E303383 T1 ATE303383 T1 AT E303383T1 AT 00989272 T AT00989272 T AT 00989272T AT 00989272 T AT00989272 T AT 00989272T AT E303383 T1 ATE303383 T1 AT E303383T1
Authority
AT
Austria
Prior art keywords
treatment
gsk3
glycogen synthase
synthase kinase
disorders
Prior art date
Application number
AT00989272T
Other languages
English (en)
Inventor
John M Nuss
Xiaohui A Zhou
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE303383T1 publication Critical patent/ATE303383T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00989272T 1999-12-17 2000-12-14 Bizyklische inhibitoren von glycogen synthase kinase 3 ATE303383T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17240399P 1999-12-17 1999-12-17
PCT/US2000/034049 WO2001044246A1 (en) 1999-12-17 2000-12-14 Bicyclic inhibitors of glycogen synthase kinase 3

Publications (1)

Publication Number Publication Date
ATE303383T1 true ATE303383T1 (de) 2005-09-15

Family

ID=22627574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989272T ATE303383T1 (de) 1999-12-17 2000-12-14 Bizyklische inhibitoren von glycogen synthase kinase 3

Country Status (11)

Country Link
US (2) US6800632B2 (de)
EP (1) EP1240168B1 (de)
JP (1) JP2003516991A (de)
KR (1) KR100711817B1 (de)
CN (1) CN100335479C (de)
AT (1) ATE303383T1 (de)
AU (1) AU784748B2 (de)
DE (1) DE60022388T2 (de)
ES (1) ES2246927T3 (de)
HK (1) HK1049338B (de)
WO (1) WO2001044246A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1240168B1 (de) * 1999-12-17 2005-08-31 Chiron Corporation Bizyklische inhibitoren von glycogen synthase kinase 3
ES2250721T3 (es) 2001-09-21 2006-04-16 Sanofi-Aventis Derivados de 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo(1,2-a)pirimidin-5(1h)ona sustituidos para enfermedades neurodegenerativas.
EP1295885A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituierte 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)onderivate
EP1295884A1 (de) * 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)on Derivate
NZ531243A (en) * 2001-09-21 2006-08-31 Sanofi Aventis Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)one derivatives
JP2005516005A (ja) * 2001-12-07 2005-06-02 バーテクス ファーマスーティカルズ インコーポレイテッド Ｇｓｋ−３阻害剤として有用なピリミジンベースの化合物
US20070020745A1 (en) * 2002-02-11 2007-01-25 Bussiere Dirksen E Method for crystallizing human GSK3 and novel crystal structure thereof
CN1649616A (zh) * 2002-03-01 2005-08-03 希龙公司 治疗缺血的方法和组合物
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
ATE477251T1 (de) 2002-08-23 2010-08-15 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
MXPA06003607A (es) * 2003-10-16 2006-06-05 Chiron Corp Quinazolinas, quinoxalinas, quinolinas e isoquinolinas 2.6-disubstituidas como inhibidores de la cinasa raf para el tratamiento del cancer.
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
BRPI0612301A2 (pt) * 2005-06-20 2009-01-27 Decode Genetics Ehf mÉtodo para diagnosticar uma suscetibilidade para a diabete tipo ii em um indivÍduo, kit, e, mÉtodo para avaliar um indivÍduo quanto a probabilidade de resposta a um agente terapÊutico de tcf7l2
US20070026436A1 (en) * 2005-07-28 2007-02-01 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
EP1790649A1 (de) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituierte bicyclische Pyrimidone Derivaten
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101419554B1 (ko) * 2006-03-13 2014-07-17 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ­３ 억제제로서 아미노퀴놀론
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2010159210A (ja) * 2007-04-26 2010-07-22 Dainippon Sumitomo Pharma Co Ltd 縮合複素環誘導体
US8263547B2 (en) 2008-05-28 2012-09-11 Massachusetts Institute Of Technology DISC-1 pathway activators in the control of neurogenesis
WO2010053825A1 (en) 2008-10-29 2010-05-14 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
EP2598661B1 (de) 2010-07-26 2017-09-27 Biomatrica, INC. Zusammensetzungen zur stabilisierung von dna, rna und proteinen in speichel- und anderen biologischen proben während des transports und der lagerung bei umgebungstemperaturen
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CN102827160B (zh) * 2011-06-16 2015-11-18 上海阳帆医药科技有限公司 PI3K或PI3K/m-TOR通路抑制剂及其在药学中的用途
EP2554662A1 (de) 2011-08-05 2013-02-06 M Maria Pia Cosma Verfahren zur Behandlung von Netzhautdegenerationserkrankungen
EP2934572A4 (de) 2012-12-20 2016-11-23 Biomatrica Inc Formulierungen und verfahren zur stabilisierung von pcr-reagenzien
EP3007556B1 (de) 2013-06-13 2020-05-20 Biomatrica, INC. Zellstabilisierung
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
EP3231434A1 (de) 2016-04-14 2017-10-18 Fundacio Centre de Regulacio Genomica Verfahren zur behandlung von parkinsonismus
RU2663913C1 (ru) * 2016-11-17 2018-08-13 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Твердая лекарственная форма антидиабетического препарата на основе N-замещенного производного амринона - ингибитора киназы гликогенсинтазы
WO2018217766A1 (en) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Kcc2 expression enhancing compounds and uses thereof
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN115626922A (zh) * 2021-04-29 2023-01-20 苏州恩华生物医药科技有限公司 5,6,7,8-四氢吡啶并[4,3-d]嘧啶-4-醇衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA764962A (en) * 1962-03-22 1967-08-08 Ohnacker Gerhard Pyrido-pyrimidines
AU7692696A (en) * 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
EP1240168B1 (de) * 1999-12-17 2005-08-31 Chiron Corporation Bizyklische inhibitoren von glycogen synthase kinase 3

Also Published As

Publication number Publication date
HK1049338B (en) 2005-10-21
US20030008866A1 (en) 2003-01-09
EP1240168A1 (de) 2002-09-18
KR100711817B1 (ko) 2007-05-02
AU2580201A (en) 2001-06-25
CN1434824A (zh) 2003-08-06
US6800632B2 (en) 2004-10-05
HK1049338A1 (en) 2003-05-09
JP2003516991A (ja) 2003-05-20
KR20020061647A (ko) 2002-07-24
AU784748B2 (en) 2006-06-08
DE60022388T2 (de) 2006-06-14
DE60022388D1 (de) 2005-10-06
US20010044436A1 (en) 2001-11-22
EP1240168B1 (de) 2005-08-31
CN100335479C (zh) 2007-09-05
WO2001044246A8 (en) 2001-10-25
ES2246927T3 (es) 2006-03-01
WO2001044246A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
ATE303383T1 (de) Bizyklische inhibitoren von glycogen synthase kinase 3
ATE384704T1 (de) Pyrazin-basierte hemmer der glycogen-synthase- kinase 3
ATE274510T1 (de) Glycogen synthase kinase 3 inhibitoren
ATE477251T1 (de) Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
WO2002020495A3 (en) Inhibitors of glycogen synthase kinase 3
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
EP1202736A4 (de) Verwendung von nikotin in der angiogenese und der vaskulogenese
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
PT1187918E (pt) Antagonistas de tek
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
MXPA04002982A (es) Derivados de pirrolidinona.
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
DK1220852T3 (da) Substituerede diazepaner
DK1441723T3 (da) Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension
NO20042138L (no) Forbindelser og fremgangsmate for behandling av hyperaktiv blaere
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
EP1233075A3 (de) BDNF Polymorphismus und Vereinigung mit doppelpoliger Geistesgestörtheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1240168

Country of ref document: EP